Is Wegovy Good for Your Heart?

What the SELECT trial actually found, and what it didn't

A lot of people assume that weight-loss medicines are purely cosmetic tools. The SELECT trial, published in the New England Journal of Medicine, directly challenged that assumption. It enrolled 17,604 adults across 45 countries, all had established cardiovascular disease, all had a BMI of 27 or above, none had type 2 diabetes. Over roughly three and a half years, those taking 2.4mg semaglutide weekly were around 20% less likely to experience a major cardiovascular event (heart attack, non-fatal stroke, or cardiovascular death) than those on placebo.

That's a meaningful reduction, and it persuaded the MHRA to grant Wegovy a UK licence specifically for cardiovascular risk reduction, something the original weight management licence didn't cover. If you want to understand what the wider semaglutide cardiovascular evidence looks like, the trial sits at the centre of it.

What SELECT didn't show (and this matters) is that everyone taking Wegovy gets a cardiovascular benefit proportional to how much weight they lose. Researchers found the event reduction appeared early, before significant weight loss had occurred, suggesting some of the effect is independent of the scales. That doesn't mean the weight loss is irrelevant; it means the two benefits may work together rather than one explaining the other.

Who the cardiovascular finding applies to, and who it doesn't

This is where the decision gets precise. The SELECT population had specific characteristics: pre-existing cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease), BMI of 27 or higher, and no diabetes diagnosis. The licence the MHRA granted reflects those criteria. If you don't have established cardiovascular disease, you're outside the SELECT population, the trial didn't study primary prevention.

For most people starting Wegovy for weight management, the cardiovascular licence isn't what triggers the prescription. The weight management indication covers adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as high blood pressure or high cholesterol. Those conditions themselves carry heart risk, so there's clear overlap, but a prescriber treats them as distinct routes. Our Wegovy overview page sets out the full UK-licensed picture in one place.

It's also worth knowing that people with certain cardiac arrhythmias or those who've had recent acute cardiac events may require extra caution. A prescriber reviews medical history precisely because these nuances can't be handled by a questionnaire alone.

How this might affect your decision about treatment

If you have a history of heart disease and are overweight or living with obesity, Wegovy is one of the few weight-loss medicines with a dedicated UK cardiovascular licence behind it. That's clinically significant. It changes the risk-benefit conversation from "will losing weight help my heart" to "this medicine has direct trial evidence for my exact situation."

If you're weighing this up and want context on how Wegovy compares with other treatments, our page for people with existing heart conditions goes into more detail on what to discuss with a clinician. It's also fair to say that questions about potential downsides deserve the same honest treatment: what the risks look like for cardiac patients is worth reading alongside the benefit data.

Kidney function is another organ system where semaglutide trials have produced encouraging data, and the evidence on kidneys follows a similar pattern, positive signals, population-specific eligibility. The broader picture is that GLP-1 medicines are beginning to look like treatments for metabolic disease across multiple organ systems, not just a route to a lower number on the scales.

None of that changes the basic legal and clinical reality: Wegovy is a prescription-only medicine, and whether it's right for you depends on a full clinical assessment. The weight loss treatment options page puts it in context alongside other licensed approaches. For a straightforward look at what private treatment costs look like if you're considering the private route, our Wegovy price comparison guide explains what's typically included in a private prescription and what questions to ask.

Our prescribers review every consultation personally, our clinical team can speak to the cardiovascular evidence directly if it's relevant to your history. If you'd like to explore whether treatment is appropriate for your situation, you're welcome to speak to our prescribers through a free consultation.